May 2, 2022 -- Biocytogen Pharmaceuticals has entered into an evaluation and option agreement with Merck KGaA to evaluate Biocytogen’s antibodies. The agreement will give Merck KGaA the license to assess these antibodies against three specified targets.
Furthermore, Merck KGaA will have the option to gain future assets related to the product development of any therapies based on these antibodies.
The targets will be chosen through Biocytogen's Project Integrum platform, utilized alongside the company's RenMice platform. Additional targets may also be assessed through the agreement.
Merck's role will primarily involve the conduct of feasibility assays of the antibodies in addition to other activities related to the development and commercialization of potential products resulting from these antibodies.
Copyright © 2022 scienceboard.net